RTP Mobile Logo
Breast Cancer Update: Surgical Edition, Issue 1, 2012
Released July 2012

Featuring interviews with Drs Monica Morrow, Harold J Burstein, Kelly K Hunt and Lawrence J Solin. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Historically, surgery has been the primary mode of treatment for early breast cancer. The diagnostic, surgical and medical management of breast cancer, however, have escalated in complexity because of numerous advances in novel technologies and available adjunctive medical therapies. Hence, the multifaceted treatment of breast cancer now requires the input of an interdisciplinary group of expert care providers. This paradigm shift has created the challenge of ensuring that major clinical advances in local and systemic breast cancer therapy are effectively disseminated among all members of the cross-functional team. To bridge the gap between research and patient care, Breast Cancer Update for Surgeons uses one-on-one interviews with leading breast cancer investigators to efficiently distill the latest research developments in the field so that they may be incorporated into clinical practice where appropriate. By providing access to cutting-edge data and expert perspectives, this CME program assists breast surgeons in the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Use case-based learning to aid in the formulation of individualized treatment strategies for patients with breast cancer.
    • Formulate an evidence-based approach to the surgical management of breast cancer in patients with a positive sentinel lymph node biopsy.
    • Determine the utility of genomic assays in counseling patients with DCIS or ER-positive early breast cancer about their risk of recurrence and the potential benefits of radiation therapy or adjuvant chemotherapy, respectively.
    • Evaluate the long-term outcomes associated with the use of radiation therapy following breast-conserving surgery for patients with pathologically confirmed node-negative or node-positive disease.
    • Describe current disease management strategies and ongoing clinical trials comparing partial breast irradiation to standard or conventional whole breast radiation therapy.
    • Identify appropriate patients for the use of magnetic resonance imaging and screening in the management of breast cancer.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue


    HOW TO USE THIS CME ACTIVITY


    This CME activity contains an audio component. The participant should listen to the audio MP3s.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDrs Morrow, Burstein and Hunt had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr SolinAdvisory Committee: Genomic Health Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Genomic Health Inc.


    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2012
    Expiration date: July 2013

Acknowledge and close

Listen to audio:
Breast Cancer Update: Surgical Edition, Issue 1, 2012
Released July 2012

Featuring interviews with Drs Monica Morrow, Harold J Burstein, Kelly K Hunt and Lawrence J Solin. (Audio Content)

Read print: